Literature DB >> 2158828

Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment.

P Reusser1, L D Fisher, C D Buckner, E D Thomas, J D Meyers.   

Abstract

Epidemiologic and clinical characteristics of cytomegalovirus (CMV) infection and disease were analyzed retrospectively in 159 autologous marrow transplant recipients. The probability of CMV infection by day 100 after transplant was 22.5% in patients seronegative to CMV before transplant versus 61.1% in seropositive patients (P less than .0001 by logrank test). Multivariate analysis identified positive pretransplant CMV serology as the only definable risk factor for CMV infection (relative risk 1.4, P less than .0001). CMV pneumonia developed in 11 patients at a median time of 100 days after transplant and was fatal in nine cases. CMV pneumonia was associated with significantly decreased probability of survival by day 100 after transplant (relative risk of death of 16.7, P less than .0001). In contrast to earlier reports, CMV infection had no significant effect on the rapidity of platelet or neutrophil recovery after transplant as assessed by time-dependent multivariate analysis. Because the incidence of severe CMV disease is not negligible after autologous marrow transplantation, preventive measures against CMV infection are warranted, as in allogeneic marrow transplantation.

Entities:  

Mesh:

Year:  1990        PMID: 2158828

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.

Authors:  M Alterio de Goss; R Holtappels; H P Steffens; J Podlech; P Angele; L Dreher; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

Review 2.  Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

Authors:  H Hebart; L Kanz; G Jahn; H Einsele
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

3.  A cross-Canada survey of cytomegalovirus prevention and treatment practices in bone marrow transplant recipients.

Authors:  A Humar; J Lipton; H Messner; A McGeer; T Mazzulli
Journal:  Can J Infect Dis       Date:  1999-11

4.  Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection.

Authors:  J Podlech; R Holtappels; M F Pahl-Seibert; H P Steffens; M J Reddehase
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.

Authors:  James N Kochenderfer; Jessica L Simpson; Christopher D Chien; Ronald E Gress
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

6.  Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.

Authors:  So-Youn Park; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Heungsup Sung; Mi-Na Kim; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee; Sung-Han Kim
Journal:  J Clin Microbiol       Date:  2011-10-26       Impact factor: 5.948

7.  Cytomegalovirus in hematopoietic stem cell transplant recipients.

Authors:  Per Ljungman; Morgan Hakki; Michael Boeckh
Journal:  Hematol Oncol Clin North Am       Date:  2011-02       Impact factor: 3.722

8.  How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.

Authors:  Firas El Chaer; Dimpy P Shah; Roy F Chemaly
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

9.  Detection of human cytomegalovirus genome in uterus tissue.

Authors:  T Furukawa; F Jisaki; D Sakamuro; T Takegami; T Murayama
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.

Authors:  M Martin; R Mañez; P Linden; D Estores; J Torre-Cisneros; S Kusne; L Ondick; R Ptachcinski; W Irish; D Kisor
Journal:  Transplantation       Date:  1994-10-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.